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MaOBJECTIVES This study sought to evaluate the prognostic signiﬁcance of left ventricular late gadolinium enhancement
(LV-LGE) incidentally found in atrial ﬁbrillation (AF) patients who undergo ablation therapy.
BACKGROUND LV-LGE provides prognostic information in patients with ischemic and nonischemic cardiomyopathies.
However, data on the clinical signiﬁcance of incidental LV-LGE in the AF population are limited.
METHODS A total of 778 patients who were referred for radiofrequency ablation of AF underwent
cardiac magnetic resonance examinations between June 2006 and January 2013. Patients with a history of
myocardial infarction or ablation therapy were excluded. The presence of LV-LGE was assessed by experienced
imaging physicians. Patients were followed for arrhythmia recurrence after the radiofrequency ablation
procedure.
RESULTS Of 598 patients included in the study, 60% were men with a mean age of 64 years and a median AF
duration of 25 months. LV-LGE was detected in 39 patients (6.5%). There were 240 arrhythmia recurrences observed
involving 40% of patients over a median follow-up period of 52 months. On univariate analysis, age (hazard ratio
[HR]: 1.02; 95% conﬁdence interval [CI]: 1.00 to 1.03), male sex (HR: 0.63; 95% CI: 0.47 to 0.86), diabetes (HR:
1.53; 95% CI: 1.03 to 2.27), CHADS2 score (HR: 1.19; 95% CI: 1.04 to 1.36), CHA2DS2-VASc score (HR: 1.18; 95% CI:
1.08 to 1.30), left atrial (LA) ﬁbrosis (HR: 1.66; 95% CI: 1.41 to 1.96), LV-LGE (HR: 1.83; 95% CI: 1.11 to 3.03), persistent
AF (HR: 1.52; 95% CI: 1.11 to 2.09), and LA area (HR: 1.03; 95% CI: 1.01 to 1.05) were signiﬁcantly associated
with arrhythmia recurrence. The recurrence rate was 69% in patients with LV-LGE compared with 38% in patients
without LV-LGE (p < 0.001). In a multivariate model, LA ﬁbrosis and LV-LGE were independent predictors of arrhythmia
recurrence.
CONCLUSIONS In AF patients without history of myocardial infarction, LV-LGE is a signiﬁcant independent predictor of
arrhythmia recurrence after ablation therapy. (J Am Coll Cardiol Img 2015;8:793–800) © 2015 by the American College
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CMR = cardiac magnetic
resonance
DM = diabetes mellitus
HTN = hypertension
LA = left atrium
LGE = late gadolinium
enhancement
LV = left ventricle
MI = myocardial infarction
PAD = peripheral arterial
disease
PV = pulmonary vein
SRM = structural remodeling
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794A trial ﬁbrillation (AF) is the most com-mon sustained arrhythmia and canresult in heart failure (1), stroke (2),
and death (3). To achieve rhythm control,
catheter ablation is becoming more common
due to improved ablation techniques and
limited success with anti-arrhythmic drugs.
In a growing number of centers, pre-
ablation cardiac magnetic resonance (CMR)
is performed to determine if patients are
reasonable candidates for ablation therapy
(4) and to provide 3-dimensional (3D) left
atrial and pulmonary venous anatomy to
help guide catheter navigation (5). This CMR
study also provides left ventricular function
and viability information.SEE PAGE 801Left ventricular late gadolinium enhancement (LV-
LGE) has prognostic value in patients with ischemic
and nonischemic cardiomyopathies (6,7). Recently,
incidental LV-LGE found by CMR in AF patients has
been associated with mortality (8). However, the
relationship between incidental LV-LGE in AF pa-
tients and speciﬁc cardiovascular outcomes has not
been well studied. The goal of this study was to
determine whether there is an association of inci-
dental LV-LGE with cardiovascular risk factors and
cardiovascular disease processes and to study the
relationship between LV-LGE and arrhythmia recur-
rence after ablation.
METHODS
STUDY POPULATION. We retrospectively collected
data on all consecutive patients from June 2006 to
January 2013 who were referred for radiofrequency
AF ablation and underwent CMR before the proce-
dure. Of the 778 patients, 16 with known coronary
artery disease and prior myocardial infarction (MI),
48 with prior AF ablation, and 116 who did not un-
dergo ablation therapy were excluded. The ﬁnal study
population included 598 AF patients who underwent
AF ablation. In AF patients with planned ablation
therapy, CMR is the primary imaging modality for left
atrial (LA) and pulmonary venous (PV) anatomy
at our center. Contraindication for CMR included
severe renal impairment (glomerular ﬁltration rate
<30 ml/min/1.73 m2), severe claustrophobia, and the
presence of a permanent pacemaker or implantable
cardioverter-deﬁbrillator. Paroxysmal AF was deﬁned
as any AF episode that terminated spontaneously
within 7 days after onset (9). Persistent AF was
deﬁned as an AF episode that extended beyond7 days. We deﬁned prior MI by either clinical docu-
mentation of MI in the electronic medical record or
electrocardiographic evidence per Minnesota codes
1.1.1 to 1.2.8 (10). The patients’ CHADS2 and CHA2DS2-
VASc characteristics were determined by systematic
chart review. The study protocol was approved by our
Institutional Review Board.
CMR PROTOCOL. All studies were performed either
on a 1.5-T Avanto or 3-T Verio scanner (Siemens
Medical Solutions, Erlangen, Germany). The CMR
protocol consisted of cine steady state free precession
imaging for cardiac structure and function, 3D
contrast enhanced magnetic resonance angiography
for LA and PV anatomy, 2D LGE imaging for viability,
and 3D LGE for LA ﬁbrosis. 2D LGE imaging
for viability was acquired approximately 12 min
after contrast injection (0.1 mmol/kg, MultiHance
[Bracco Diagnostics, Inc., Princeton, New Jersey])
using single-shot, electrocardiogram (ECG)-triggered,
free-breathing, phase-sensitive inversion recovery
sequences in short-axis and horizontal and vertical
long-axis orientations covering the whole heart. Scan
parameters for 2D LGE imaging were as follows: 3-T –
echo time (TE) ¼ 1.1 ms, repetition time (TR) ¼ 2.5 ms,
ﬂip angle (FA) ¼ 35, pixel size ¼ 1.88  1.88  2.07
mm, slice thickness ¼ 7 mm; 1.5-T – TE ¼ 1.1 ms, TR ¼
2.5 ms, FA ¼ 45, pixel size ¼ 1.85  1.85  2.05 mm,
slice thickness ¼ 6 mm.
High-resolution LGE images for assessment of
LA ﬁbrosis were acquired 15 min after contrast injec-
tion using a 3D respiratory-navigated, ECG-gated,
inversion recovery-prepared gradient-recalled pulse
sequence. Inversion preparation was applied every
heartbeat, and fat saturation was applied immedi-
ately before data acquisition. Data acquisition was
limited to 15% of the cardiac cycle and was performed
during LA diastole. The other scan parameters for
assessment of LA LGE at 3-T were as follows: axial
imaging volume with ﬁeld-of-view (FOV) ¼ 400 
400  110 mm, voxel size ¼ 1.25  1.25  2.5 mm,
TR/TE ¼ 3.1/1.4 ms, FA ¼ 14. Scan parameters for
assessment of LA LGE at 1.5-T were as follows: axial
imaging volume with FOV ¼ 360  360  100 mm,
voxel size ¼ 1.25  1.25  2.5 mm, TR/TE ¼ 5.2/2.4 ms,
FA ¼ 20. Typical scan time for the LGE study was 6 to
12 min at 1.5-T and 5 to 9 min at 3-T, depending on
patient respiration. LGE images were interpreted by 2
experienced CMR physicians. LV-LGE was considered
present only if it was visible in all corresponding
myocardial locations on short-axis, horizontal long-
axis, and vertical long-axis images. LGE distribution
was categorized as subendocardial, mid-myocardial,
epicardial, transmural, or adjacent to right ventricu-
lar insertion points. Post-processing of LGE images
TABLE 1 Baseline Characteristics Stratiﬁed by the Presence of LV-LGE
Overall Cohort
(n ¼ 598)
LV-LGE Absent
(n ¼ 559)
LV-LGE Present
(n ¼ 39) p Value
Age, yrs 64.1  12.0 63.8  12.0 65.8  11.7 0.313
Male 360 (60.2) 336 (60.1) 24 (61.5) 0.860
Diabetes 81 (13.5) 71 (12.7) 10 (25.6) 0.022
Hypertension 366 (61.2) 337 (60.3) 29 (74.4) 0.082
Smoking history 166 (27.8) 149 (26.7) 17 (43.6) 0.022
Dyslipidemia 172 (28.8) 155 (27.7) 17 (43.6) 0.034
Prior stroke 56 (9.4) 50 (8.9) 6 (15.4) 0.183
PAD 7 (1.2) 5 (0.89) 2 (5.1) 0.017
Heart failure 54 (9.0) 45 (8.1) 9 (23.1) 0.002
Persistent AF 262 (43.8) 247 (44.2) 15 (38.5) 0.487
CHADS2 1.21  1.04 1.17  1.07 1.76  1.04 <0.001
CHA2DS2-VASc 2.14  0.06 2.09  1.53 2.85  1.37 0.003
LA ﬁbrosis, % 16.1  10.1 16.0  10.1 17.5  10.1 0.422
LV EF <55% 71 (11.9) 66 (11.8) 5 (12.8) 0.850
LA area, cm2 28.7  7.7 28.5  7.6 32.2  8.0 0.003
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; EF ¼ ejection fraction; LA ¼ left atrium; LGE ¼ late gadolinium enhancement; LV ¼ left
ventricle; PAD ¼ peripheral arterial disease.
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795for LV-LGE was performed with CVI42 software
version 5.0 (Circle Cardiovascular Imaging, Inc., Cal-
gary, Alberta, Canada) and LA ﬁbrosis was performed
with custom software (Corview, Marrek, Inc., Salt
Lake City, Utah). The amount of LV-LGE and LA
ﬁbrosis was quantiﬁed using a threshold-based
algorithm.
ABLATION AND FOLLOW-UP PROTOCOLS. The de-
tails of the PV isolation, in addition to posterior wall
and septal debulking, are described elsewhere (11). In
brief, a 10-pole circular mapping catheter (Lasso,
Biosense Webster, Diamond Bar, California) and a
3.5-mm ThermoCool ablation catheter (Biosense
Webster) were advanced into the LA for mapping and
ablation. Radiofrequency energy was delivered
with 50 Watts at a catheter tip temperature of 50C
for 5 s, guided by electrogram abolition recorded
on the Lasso catheter. Electrical isolation of the pul-
monary veins was achieved by placing ablation
lesions in a circular fashion in the PV antral region.
The additional lesions were placed along the
LA posterior wall and septum. The endpoint of
interest was atrial arrhythmia recurrence after abla-
tion. Eight day Holter monitoring was performed
routinely at 3, 6, and 12 months after ablation and
yearly thereafter. In addition, symptom-guided
Holter monitoring and 12-lead ECGs were used
to determine arrhythmia recurrence. Any sustained
atrial arrhythmia for longer than 30 s without
antiarrhythmic drug treatment after a 3-month post-
ablation blanking period was considered as recur-
rence, as suggested by Heart Rhythm Society
consensus statements (12).
STATISTICAL ANALYSIS. Continuous variables are
presented as mean and standard deviations. Categor-
ical data are presented as numbers and percentages.
Comparisons between 2 groups were made using the
Student t test or Mann-Whitney non-parametric test
for continuous variables and using the chi-square
test or Fisher exact tests for categorical variables, as
appropriate. Univariate and multivariate logistic
regression models were used to determine predictors
of LV-LGE. Spearman’s correlation was used to assess
the relationship between extent of LV-LGE and atrial
ﬁbrosis in AF patients with LV-LGE. A Cox regression
model was used to determine the hazard ratio (HR) for
arrhythmia recurrence. The best overall multivariate
models for LV-LGE were sought by stepwise forward
selection with a probability to enter set at p ¼ 0.05.
Arrhythmia recurrence curves were determined ac-
cording to Kaplan-Meier methods, and comparison of
recurrence rate was performed using a log-rank test.
The Harrell concordance C statistic for arrhythmia
recurrence outcomeswas used to assess the increase inprognostic accuracy resulting from adding LV-LGE
to the model with the set of covariates that are risk
factors for arrhythmia recurrence after ablation ther-
apy. A p value of <0.05 was considered statistically
signiﬁcant, and all reported p values are 2-tailed. All
analyses were performed using STATA version 12
(StataCorp, College Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. We included 598 AF
patients without history of MI who underwent CMR
and ﬁrst AF ablation. There were 360 men (60%) with
a mean age of 64.1  12.0 years and a median AF
duration of 25 months (range 6 to 69 months). Two
hundred sixty-two patients (44%) had paroxysmal
AF, and 336 patients (66%) had persistent AF. There
were 81 patients (14%) with diabetes mellitus (DM),
366 patients (61%) with hypertension (HTN), and 54
patients (9%) with heart failure. Patients with LV-LGE
were found to have a signiﬁcantly higher prevalence
of DM, dyslipidemia, peripheral arterial disease
(PAD), heart failure, and smoking history. CHADS2,
CHA2DS2-VASc, and LA area were also higher
compared with patients without LV-LGE. The clinical
demographics of the patients stratiﬁed by the pres-
ence and absence of LGE are represented in Table 1.
LV-LGE. In our AF patient cohort without history of
MI, LV-LGE was found in 39 patients (6.5%) with an
average LV-LGE extent of 2.1  2.1%. Of these pa-
tients, 34 (89.5%) had a normal LV ejection frac-
tion of $55%. The observed pattern of LV-LGE was
ischemic in 46% of the patients (subendocardial in
FIGURE 1 LV-LGE Pattern Distribution in AF Patients
Transmural
Subendocardial
Mid-Myocardial
Epicardial
RV insertion
46% 26%
20%5%3%
Pie chart showing the left ventricle late gadolinium enhancement (LV-LGE) pattern distribution in the retrospective cohort of atrial ﬁbrillation
(AF) patients without a history of myocardial infarction (MI). An ischemic (subendocardial and transmural) pattern was found in almost one-half
(46%) of these patients.
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79610 [26%] and transmural in 8 [20%]) and nonischemic
in 54% (mid-myocardial in 18 [46%], epicardial in
1 [3%], and right ventricle [RV] insertional in 2 [5%])
(Figure 1). Examples are shown in Figure 2. In the 18
patients with LV-LGE in an ischemic pattern, there
was 1 (6%) who subsequently underwent a revascu-
larization procedure. Of 21 patients with LV-LGE
in a nonischemic pattern, 18 (85.7%) had normal LVFIGURE 2 Representative LV-LGE Images
LGE (arrows) in horizontal long- and short-axis images in AF patients w
(C) mid-myocardial LGE; (D) right ventricular (RV) insertional LGE. Abbrejection fraction, 2 (9.5%) were diagnosed with
hypertrophic cardiomyopathy, and 1 (4.8%) was
diagnosed with dilated cardiomyopathy.
UNIVARIATE AND MULTIVARIATE ASSOCIATIONS
WITH LV-LGE. On univariate analysis, DM (odds ratio
[OR] ¼ 2.37; 95% conﬁdence interval [CI]: 1.11 to 5.07),
dyslipidemia (OR: 2.01; 95% CI: 1.04 to 3.89),
PAD (OR: 5.99; 95% CI: 1.12 to 31.92), heart failureithout a history of MI. (A) Absence of LGE; (B) subendocardial LGE;
eviations as in Figure 1.
TABLE 3 Multivariate Analyses of Atherosclerosis Risk Factors for Association
With LV-LGE
Multivariate Analyses
(Atherosclerotic Pathway)
Odds Ratio 95% CI p Value
Age, yrs Removed from the model due to insigniﬁcance
Male Removed from the model due to insigniﬁcance
Diabetes 2.35 1.08–5.12 0.031
Hypertension Removed from the model due to insigniﬁcance
Dyslipidemia 1.71 0.87–3.35 0.121
Smoking 1.98 1.01–3.88 0.047
PAD 5.18 0.93–29.00 0.061
Prior stroke Removed from the model due to insigniﬁcance
Abbreviations as in Tables 1 and 2.
TABLE 4 Multivariate Analyses of Embolic Risk Factors for
Association With LV-LGE
Multivariate Analyses
(Embolic Pathway)
Odds Ratio 95% CI p Value
CHA2DS2-VASc 1.32 1.05–1.65 0.017
LA ﬁbrosis 1.00 0.96–1.03 0.850
LA area 1.07 1.03–1.12 0.002
Persistent AF 1.14 0.53–2.45 0.741
Abbreviations as in Tables 1 and 2.
TABLE 2 Univariate and Multivariate Analyses for Associations With LV-LGE
Univariate Analyses
Multivariate Analyses
(Stepwise Elimination to 4 Variables)
Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
Age, yrs 1.01 0.99–1.04 0.352
Male 1.06 0.55–2.07 0.860
Diabetes 2.37 1.11–5.07 0.026
Hypertension 1.91 0.91–4.00 0.086
Dyslipidemia 2.01 1.04–3.89 0.037
Smoking 2.13 1.10–4.11 0.025
PAD 5.99 1.12–31.92 0.036 6.88 1.19–39.72 0.031
Heart failure 3.43 1.53–7.66 0.003 2.51 1.05–5.98 0.038
Prior stroke 1.85 0.74–4.63 0.188
CHADS2 1.58 1.20–2.07 0.001
CHA2DS2-VASc 1.35 1.10–1.65 0.003 1.22 0.98–1.52 0.076
LA ﬁbrosis 1.01 0.98–1.05 0.421
Persistent AF 0.79 0.41–1.54 0.487
LV EF <55% 0.91 0.34–2.40 0.850
LA area 1.06 1.02–1.10 0.004 1.05 1.01–1.10 0.01
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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797(OR: 3.43; 95% CI: 1.53 to 7.66), smoking history
(OR: 2.13; 95% CI: 1.10 to 4.11), CHADS2 (OR: 1.58; 95%
CI: 1.20 to 2.07), CHA2DS2-VASc (OR: 1.18; 95% CI: 1.08
to 1.30), and LA area (OR: 1.03; 95% CI: 1.01 to 1.05)
provided signiﬁcant unadjusted associations with
LV-LGE. In multivariate models with stepwise selec-
tion, PAD (OR: 6.88; 95% CI: 1.19 to 39.72), heart failure
(OR: 2.51; 95% CI: 1.05 to 5.98), and LA area (OR: 1.05;
95% CI: 1.01 to 1.10) provided signiﬁcant adjusted as-
sociations with LV-LGE (Table 2). When including only
atherosclerotic risk factors in the multivariate model,
DM (OR: 2.35; 95% CI: 1.08 to 5.12) and smoking history
(OR: 1.98; 95% CI: 1.01 to 3.88) provided signiﬁcant
adjusted associations with LV-LGE (Table 3). When
including only embolic risk factors in the multivariate
model, CHA2DS2-VASc (OR: 1.32; 95% CI: 1.05 to 1.65)
and LA area (OR: 1.07; 95% CI: 1.03 to 1.12) pro-
vided signiﬁcant adjusted associations with LV-LGE
(Table 4). There is no signiﬁcant correlation between
the extent of LV-LGE and atrial ﬁbrosis (Spearman’s
rho ¼ –0.32, p ¼ 0.066).
ARRHYTHMIA RECURRENCE. There were 240 arrhy-
thmia recurrences (40%) over a median follow-up
period of 52 months. The recurrence rate was signif-
icantly higher in patients with incidental LV-LGE
than it was in patients without incidental LV-LGE
(27 [69%] vs. 213 [38%]; p < 0.001). Median time to
recurrence in this cohort was 194 days.
UNIVARIATE AND MULTIVARIATE ASSOCIATIONS
WITH ARRHYTHMIA RECURRENCE. On univariate
analysis, age (HR: 1.02; 95% CI: 1.00 to 1.03), male sex
(HR: 0.63; 95% CI: 0.47 to 0.86), DM (HR: 1.53; 95% CI:
1.03 to 2.27), CHADS2 (HR: 1.19; 95% CI: 1.04 to 1.36),
CHA2DS2-VASc (HR: 1.18; 95% CI: 1.08 to 1.30), LA
ﬁbrosis (HR: 1.66; 95% CI: 1.41 to 1.96), LV-LGE
(HR: 1.83; 95% CI: 1.11 to 3.03), persistent AF (HR:
1.52; 95% CI: 1.11 to 2.09), and LA area (HR: 1.03; 95%
CI: 1.01 to 1.05) provided signiﬁcant association with
arrhythmia recurrence. In multivariate models, only
LA ﬁbrosis (HR: 1.03; 95% CI: 1.02 to 1.05) and LV-LGE
(HR: 1.81; 95% CI: 1.12 to 2.91) provided a signiﬁcant
association with arrhythmia recurrence (Table 5).
A Kaplan-Meier curve showing a signiﬁcant differ-
ence in arrhythmia recurrence between patients with
and without incidental LV-LGE is shown in Figure 3.
Harrell’s C statistics were signiﬁcantly improved
when adding LV-LGE to LA ﬁbrosis from 0.605 to
0.627 (an improvement of 0.022; 95% CI: 0.004 to
0.400; p ¼ 0.014) and to the model that includes
hypertension, AF duration, persistent AF, LV
dysfunction, LA size, and ﬁbrosis from 0.649 to 0.663
(an improvement of 0.014; 95% CI: 0.016 to 0.026;
p ¼ 0.026) for prediction of the arrhythmia recurrence
after ablation therapy.DISCUSSION
The purpose of this study was to evaluate the prog-
nostic value of LV-LGE in AF patients who underwent
TABLE 5 Univariate and Multivariate Analyses for Associations With
Arrhythmia Recurrence
Univariate Analyses Multivariate Analyses
Hazard Ratio 95% CI p Value Hazard Ratio 95% CI p Value
Age, yrs 1.02 1.00–1.03 0.019 0.99 0.98–1.02 0.990
Male 0.63 0.47–0.86 0.003 0.83 0.50–1.37 0.462
Diabetes 1.53 1.03–2.27 0.035 1.24 0.71–2.16 0.450
Hypertension 1.37 0.99–1.90 0.055 1.38 0.83–2.28 0.210
Dyslipidemia 1.22 0.88–1.69 0.234 1.09 0.79–1.51 0.587
Smoking 1.33 0.97–1.84 0.08 1.25 0.90–1.73 0.185
PAD 1.50 0.48–4.69 0.489 2.72 0.78–9.5 0.117
Heart failure 1.15 0.70–1.90 0.583 0.90 0.46–1.76 0.759
Prior stroke 1.19 0.73–1.93 0.488 0.90 0.57–1.44 0.670
CHADS2 1.19 1.04–1.36 0.009
CHA2DS2-VASc 1.18 1.08–1.30 <0.001 1.01 0.71–1.44 0.949
LA ﬁbrosis (1% increase) 1.66 1.41–1.96 <0.001 1.03 1.02–1.05 <0.001
LV-LGE 1.83 1.11–3.03 0.018 1.81 1.12–2.91 0.015
Persistent AF 1.52 1.11–2.09 0.01 0.75 0.54–1.04 0.089
LV EF <55% 1.03 0.70–1.53 0.878 1.18 0.74–1.88 0.484
LA area 1.03 1.01–1.05 0.003 1.01 0.99–1.03 0.420
Abbreviations as in Tables 1 and 2.
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798ablation therapy. This study produced several
important ﬁndings. First, the presence of LV-LGE in
AF patients was associated with atherosclerotic and
embolic risk factors. An LV-LGE pattern consistent
with an ischemic process was detected in 46% of
patients with incidentally discovered LV-LGE. The
presence of LV-LGE in the remaining patients is pre-
sumably due to non-ischemic etiology. Second, theAnalysis According to LV-LGE
Follow-up (Days)
90 180
Log rank test p < 0.01
 554 454 415 405 393 385 378 375
37 27 23 20 18 15 13 13
270 360 450 540 630 720
LV LGE absent LV LGE present
howing the difference in arrhythmia-free survival after 2 years of
with and without incidental LV-LGE. Abbreviations as in Figure 1.presence of LV-LGE was a signiﬁcant, independent
predictor of arrhythmia recurrence after AF ablation
therapy, suggesting that incidental LV-LGE may be an
additive risk factor for arrhythmia recurrence.
LV-LGE has been validated against histologic
ﬁndings in animal models and in humans where it
has been shown to correlate with myocardial ﬁbrosis
(13–17). Although it is not speciﬁc (18), the ischemic
LGE pattern (subendocardial/transmural) usually re-
presents ischemic heart disease (6,19). On the other
hand, nonischemic LGE representing focal myocar-
dial ﬁbrosis can be found in nonischemic cardiomy-
opathies (15,20) and other cardiac conditions (21–23).
In AF populations, the data on incidental LV-LGE
patterns and pathophysiology are still limited. In
our AF patients without history of MI, LV-LGE was
detected in 39 patients (6.5%). In almost one-half of
these patients, LV-LGE was seen in an ischemic
pattern, which is similar to the ﬁndings in the earlier
study from Neilan et al. (8). We further found that
atherosclerotic and embolic risk factors were inde-
pendent predictors of LV-LGE. This could be due to
unrecognized coronary artery disease or micro-
embolism in AF patients causing an ischemic LV-LGE
pattern. However, the mechanism involved in the
development of nonischemic LV-LGE patterns in AF
patients is still unclear. This could result from LV
remodeling associated with chronic AF (24) or aging
(25), or from another multifactorial, genetic process.
It may also be reﬂective of the presence of comor-
bidities and associated myocardial disease.
The prognostic value of LV-LGE has been applied
to ischemic and nonischemic cardiomyopathies (6,7)
and aortic stenosis (26). Recently, unanticipated
LV-LGE in AF patients was shown to be an indepen-
dent predictor of mortality (8). In our study, we
report the prognostic value of incidental LV-LGE for
AF ablation outcomes. Patients with LV-LGE had
arrhythmia recurrence rates as high as 69% in our
cohort. Mechanistically, the presence of ﬁbrosis could
render the ventricle less compliant, resulting in
impaired relaxation with increased LV ﬁlling pres-
sures (27), leading to increased LA pressures and
structural remodeling (SRM) (28), which is a substrate
for AF. The extent of myocardial ﬁbrosis by LGE has
been shown to be correlated with severity of diastolic
dysfunction (29). This mechanism is further sup-
ported by data from our cohort showing signif-
icantly larger LA sizes in patients with LV-LGE.
Similar to earlier studies (30), we also showed LA
ﬁbrosis as an independent predictor of AF ablation
outcome. Interestingly, there was no signiﬁcant dif-
ference between LA ﬁbrosis, a hallmark of SRM, be-
tween patients with and without incidental LV-LGE.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In patients with
AF, CMR provides LA and pulmonary venous anatomy as well as
LA ﬁbrosis information that can be used for pre-ablation plan-
ning. Additionally, left ventricular LV-LGE assessment provides
supplementary data that may help further improve patient
selection for ablation therapy.
TRANSLATIONAL OUTLOOK: Future prospective studies
with implementation of LV-LGE into the clinical decision-making
strategies for ablation therapy are warranted to validate the
incremental prognostic implications of LV-LGE identiﬁed on CMR
in the AF population.
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799Thus, incidental LV-LGE was an additive predictor of
arrhythmia recurrence after ablation.
With superior spatial resolution compared to
ultrasound (31,32) and the ability to be coregistered
with electroanatomical mapping systems (12), CMR
and computed tomographic angiography are being
used to delineate LA and PV anatomy. To date, there
are no guidelines to support the use of CMR as the
primary imaging modality to visualize LA and PV
anatomy before ablation therapy. Our study empha-
sizes the advantages of CMR imaging in the AF pop-
ulation, namely the important prognostic information
provided by assessment of LA ﬁbrosis and incidental
LV-LGE. This information allows clinicians to indi-
vidualize therapeutic approaches by determining
which patients are appropriate for ablation therapy.
These ﬁndings also provide prognostic value in terms
of mortality (8). In situations where CMR is available,
it should be considered as the primary imaging
modality in arrhythmia patients with no magnetic
resonance imaging (MRI) contraindications.
STUDY LIMITATIONS
We do not have data on diastolic LV function to look
for association with incidental LV-LGE. However,
there are results from a prior study that suggest an
association between LV-LGE and diastolic dysfunction
(29). Multiple comparisons are made in our analysis
without adjustment methods, and there is a possibility
that spurious associations may appear statistically
signiﬁcant because of the number of comparisons be-
ing performed. However, LV-LGE is our primary pre-
dictor of interest for association with arrhythmia
recurrence. We consider LV-LGE the only variable that
is a conﬁrmatory ﬁnding to the primary hypothesis.
Because this involves only 1 variable, there is no
increased false positive issue for LV-LGE being an in-
dependent predictor for arrhythmia recurrence.
Although there was signiﬁcant improvement in the
prediction of arrhythmia recurrence after ablation
therapy, the absolute changes in predictive accuracy
were modest when adding LV-LGE to the current
clinical risk factors. This represents the challenge of
introducing additional factors, such as LV-LGE, into
the risk prediction model. These ﬁndings could be
further validated with subsequent prospective study.
Follow-up and post-ablation monitoring for recurrentarrhythmia was performed using ambulatory ECG
monitoring as well as symptom-driven 12-lead ECGs,
as recommended by the 2012 HRS/EHRA/ECAS Expert
Consensus Statement on catheter and surgical abla-
tion of atrial ﬁbrillation (12). However, this method is
known to potentially underrepresent the burden of
recurrent atrial arrhythmia and presents a limitation
to this and other studies using the same metrics. The
etiology of nonischemic LV-LGE in AF remains unclear
on the basis of retrospective investigation from our
medical record review. Future studies addressing this
question are required.
CONCLUSIONS
In this large cohort of AF patients without a history of
MI, incidental ﬁnding of LV-LGE was shown to be
an important, independent predictor of arrhythmia
recurrence after ablation therapy. These results
further emphasize the role of LGE-MRI in deciding
the suitability of ablation therapy for individual AF
patients.
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